<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487318</url>
  </required_header>
  <id_info>
    <org_study_id>13358</org_study_id>
    <nct_id>NCT00487318</nct_id>
  </id_info>
  <brief_title>Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin</brief_title>
  <official_title>A Randomized Controlled Trial of Adding Fluvastatin to Standard Medical Treatment (SMT) and a Pilot Trial of Rosuvastatin and Other Statins With SMT, for Patients Infected With Chronic Hepatitis C Who Are Naive to Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bader, Ted, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Bader, Ted, M.D.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV
      therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with
      the Veterans Administration. It is a randomized control format including genotypes 1 and 3.
      There will also be pilot arms for HCV carriers who present for screening already on a
      statin, who will be allowed to stay on their current statin or switched to another statin.
      In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given
      per FDA package insert.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Viral response</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load at 4, 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1 Plus statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of the standard of care for hepatitis C of peginterferon and ribavirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>peginterferon/RBV</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin</intervention_name>
    <description>Add fluvastatin at 20-40 mg/day to standard of care</description>
    <arm_group_label>Arm 1 Plus statin</arm_group_label>
    <other_name>Lescol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not previously treated.

          -  Off alcohol and marijuana for 6 months

          -  HCV RNA positive

        Exclusion Criteria:

          -  HIV positive

          -  Advanced liver disease

          -  Advanced cardiopulmonary disease

          -  Chronic renal failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted F Bader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC and VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 20, 2012</lastchanged_date>
  <firstreceived_date>June 15, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bader, Ted, M.D.</investigator_affiliation>
    <investigator_full_name>Ted Bader, MD</investigator_full_name>
    <investigator_title>Director of Liver Diseases, VA Medical Center</investigator_title>
  </responsible_party>
  <keyword>fluvastatin</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>not previously treated with pegylated interferon and ribavirin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
